8.72 -0.02 (-0.23%)
After hours: 7:59PM EDT
Previous close | 9.01 |
Open | 8.80 |
Bid | 8.75 x 3100 |
Ask | 8.77 x 3200 |
Day's range | 8.53 - 8.97 |
52-week range | 8.06 - 33.79 |
Volume | 8,815,614 |
Avg. volume | 15,359,388 |
Market cap | 1.821B |
Beta (5Y monthly) | 0.76 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.07 |
Earnings date | 01 Mar 2021 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 15.63 |
Investors need to pay close attention to Inovio (INO) stock based on the movements in the options market lately.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into Inovio Pharmaceuticals Inc. (NasdaqGS: INO).
In this Motley Fool Live video recorded on March 26, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss why Inovio Pharmaceuticals' (NASDAQ: INO) technology may result in a longer timeline to commercialization. Corinne Cardina: I have a question for you about the Inovio device. Do you think that this delivery device puts Inovio at a disadvantage compared to vaccines that do not require a device?